Leveraging Hypomethylating Agents for Better MDS Therapy

Terrence J. Bradley, Justin Watts, Ronan T Swords

Research output: Contribution to journalArticle

Abstract

Purpose of Review: Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond, most responses are not durable, and the only hope for a cure is allogeneic stem cell transplant. New therapies to improve outcomes are urgently needed. Recent Findings: Clinical trials combining standard hypomethylating agents with novel experimental agents are underway in an effort to improve clinical outcomes in MDS patients. Several of these small molecules have demonstrated the ability to augment the response rates of hypomethylating agents alone, including complete remission rates, in both the front line and refractory settings. Summary: Combination approaches utilizing hypomethylating agents and novel-targeted therapies have demonstrated the ability to improve response rates in MDS patients in both the front line and salvage settings, and thus may change the standard of care.

Original languageEnglish (US)
JournalCurrent Hematologic Malignancy Reports
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Myelodysplastic Syndromes
Standard of Care
Therapeutics
Stem Cells
Clinical Trials
Transplants
Survival

Keywords

  • Acute myeloid leukemia
  • Hypomethylating agents
  • Immunotherapy
  • Isocitrate dehydrogenase
  • Myelodysplastic syndrome
  • Pevonedistat

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Leveraging Hypomethylating Agents for Better MDS Therapy. / Bradley, Terrence J.; Watts, Justin; Swords, Ronan T.

In: Current Hematologic Malignancy Reports, 01.01.2018.

Research output: Contribution to journalArticle

@article{15124868e06347849af2e4a06a9e10c6,
title = "Leveraging Hypomethylating Agents for Better MDS Therapy",
abstract = "Purpose of Review: Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond, most responses are not durable, and the only hope for a cure is allogeneic stem cell transplant. New therapies to improve outcomes are urgently needed. Recent Findings: Clinical trials combining standard hypomethylating agents with novel experimental agents are underway in an effort to improve clinical outcomes in MDS patients. Several of these small molecules have demonstrated the ability to augment the response rates of hypomethylating agents alone, including complete remission rates, in both the front line and refractory settings. Summary: Combination approaches utilizing hypomethylating agents and novel-targeted therapies have demonstrated the ability to improve response rates in MDS patients in both the front line and salvage settings, and thus may change the standard of care.",
keywords = "Acute myeloid leukemia, Hypomethylating agents, Immunotherapy, Isocitrate dehydrogenase, Myelodysplastic syndrome, Pevonedistat",
author = "Bradley, {Terrence J.} and Justin Watts and Swords, {Ronan T}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s11899-018-0477-3",
language = "English (US)",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Leveraging Hypomethylating Agents for Better MDS Therapy

AU - Bradley, Terrence J.

AU - Watts, Justin

AU - Swords, Ronan T

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose of Review: Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond, most responses are not durable, and the only hope for a cure is allogeneic stem cell transplant. New therapies to improve outcomes are urgently needed. Recent Findings: Clinical trials combining standard hypomethylating agents with novel experimental agents are underway in an effort to improve clinical outcomes in MDS patients. Several of these small molecules have demonstrated the ability to augment the response rates of hypomethylating agents alone, including complete remission rates, in both the front line and refractory settings. Summary: Combination approaches utilizing hypomethylating agents and novel-targeted therapies have demonstrated the ability to improve response rates in MDS patients in both the front line and salvage settings, and thus may change the standard of care.

AB - Purpose of Review: Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond, most responses are not durable, and the only hope for a cure is allogeneic stem cell transplant. New therapies to improve outcomes are urgently needed. Recent Findings: Clinical trials combining standard hypomethylating agents with novel experimental agents are underway in an effort to improve clinical outcomes in MDS patients. Several of these small molecules have demonstrated the ability to augment the response rates of hypomethylating agents alone, including complete remission rates, in both the front line and refractory settings. Summary: Combination approaches utilizing hypomethylating agents and novel-targeted therapies have demonstrated the ability to improve response rates in MDS patients in both the front line and salvage settings, and thus may change the standard of care.

KW - Acute myeloid leukemia

KW - Hypomethylating agents

KW - Immunotherapy

KW - Isocitrate dehydrogenase

KW - Myelodysplastic syndrome

KW - Pevonedistat

UR - http://www.scopus.com/inward/record.url?scp=85054330394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054330394&partnerID=8YFLogxK

U2 - 10.1007/s11899-018-0477-3

DO - 10.1007/s11899-018-0477-3

M3 - Article

C2 - 30267380

AN - SCOPUS:85054330394

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -